Most cited papers from Agenus (United States)

Agenus (United States)

What are the most cited papers from Agenus (United States)?

The most cited paper from Agenus (United States) is "Actively personalized vaccination trial for newly diagnosed glioblastoma" (Norbert Hilf et al., 2018), with 954 citations. Next come "Recombinant Glycoprotein Vaccine for the Prevention of Genital HSV-2 Infection" (492) and "An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial" (333).

Published TypeFieldAccessCitations

Showing 50 of 61 papers. Every paper with more than 27 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Actively personalized vaccination trial for newly diagnosed glioblastoma Norbert Hilf et al. · Nature	19 Dec 2018	954
2	Recombinant Glycoprotein Vaccine for the Prevention of Genital HSV-2 Infection Lawrence Corey, Andria G. M. Langenberg, Rhoda L. Ashley et al. · JAMA	28 Jul 1999	492
3	An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial Christopher G. Wood, Pramod Kumar Srivastava, Ronald M. Bukowski et al. · The Lancet	Jul 2008	333
4	The PROTACtable genome Melanie Schneider, Chris J. Radoux, Andrew Hercules et al. · Nature Reviews Drug Discovery Review	20 Jul 2021	259
5	Heat Shock Proteins gp96 and hsp70 Activate the Release of Nitric Oxide by APCs Naveed Panjwani, L. G. Popova, Pramod Kumar Srivastava · The Journal of Immunology	Mar 2002	259
6	Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment Victor Andrés Arrieta, Crismita Dmello, Daniel James McGrail et al. · Journal of Clinical Investigation Open access	16 Jan 2023	241
7	Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Vincenzo Mazzaferro, Jorgelina Clara Coppa, Matteo Giovanni Carrabba et al. · PubMed	15 Aug 2003	240
8	Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study David M. O'Malley, Maryna Neffa, Bradley J. Monk et al. · Journal of Clinical Oncology Open access	21 Dec 2021	192
9	Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution Vaia Florou, Andrew Eric Rosenberg, Eric Wieder et al. · Journal for ImmunoTherapy of Cancer Open access	8 Aug 2019	186
10	Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy Benjamin J. Wolf, Jiyoung Elizabeth Choi, Mark A. Exley · Frontiers in Immunology Open access	2 Mar 2018	154
11	A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer Tomislav Dragovich, David S. Mendelson, Sandra E Kurtin et al. · Cancer Chemotherapy and Pharmacology	22 May 2006	138
12	Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial Andrea J. Bullock et al. · Nature Medicine Open access	13 Jun 2024	137
13	A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients Lorenzo Pilla et al. · Cancer Immunology Immunotherapy Open access	7 Oct 2005	137
14	Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer David M. O’Malley, Ana Oaknin, Bradley J. Monk et al. · Gynecologic Oncology Open access	25 Aug 2021	129
15	Mutation-Derived Neoantigens for Cancer Immunotherapy John C. Castle, Mohamed Uduman, Simarjot Singh Pabla et al. · Frontiers in Immunology Open access	7 Aug 2019	122
16	Lessons from randomized phase III studies with active cancer immunotherapies – Outcomes from the 2006 Meeting of the Cancer Vaccine Consortium (CVC) Lothar H. Finke, Kerry Wentworth, Brent A. Blumenstein et al. · Vaccine	Sep 2007	122
17	Human Tumor-Derived Heat Shock Protein 96 Mediates In Vitro Activation and In Vivo Expansion of Melanoma- and Colon Carcinoma-Specific T Cells Licia Rivoltini, Chiara Castelli, Matteo Giovanni Carrabba et al. · The Journal of Immunology Open access	Oct 2003	121
18	QS-21 structure/function studies: effect of acylation on adjuvant activity Gui Liu, Christine Anderson, Heidi Scaltreto et al. · Vaccine	Jun 2002	114
19	HLA and proteasome expression body map Sebastian Boegel, Martin Löwer, Thomas Bukur et al. · BMC Medical Genomics Open access	27 Mar 2018	113
20	Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor Joseph Elan Grossman, Divya Vasudevan, Cailin E. Joyce et al. · Oncogene Open access	26 Jan 2021	110
21	Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens Jeremy D. Waight, Dhan Chand, Sylvia Dietrich et al. · Cancer Cell Open access	Jun 2018	104
22	Observation of dissipative chlorophyll-to-carotenoid energy transfer in light-harvesting complex II in membrane nanodiscs Minjung Son, Alberta Pinnola, Samuel C. Gordon et al. · Nature Communications Open access	10 Mar 2020	102
23	Induction of CD1-Restricted Immune Responses in Guinea Pigs by Immunization with Mycobacterial Lipid Antigens Kenji Hiromatsu, Christopher C. Dascher, Kenneth P. LeClair et al. · The Journal of Immunology Open access	Jul 2002	97
24	TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression Jelle Scholtalbers, Sebastian Boegel, Thomas Bukur et al. · Genome Medicine Open access	20 Nov 2015	96
25	Facts and Hopes in Immunotherapy of Pancreatic Cancer Bruno Bockorny, Joseph Elan Grossman, Manuel M. Hidalgo · Clinical Cancer Research	Jul 2022	93
26	CSF1R inhibition depletes tumor-associated macrophages and attenuates tumor progression in a mouse sonic Hedgehog-Medulloblastoma model I‐Li Tan, Raquel Duque do Nascimento Arifa, Harikrishna Rallapalli et al. · Oncogene Open access	6 Nov 2020	87
27	Heat Shock Protein-Mediated Cross-Presentation of Exogenous HIV Antigen on HLA Class I and Class II Devi SenGupta, Philip J. Norris, Todd J. Suscovich et al. · The Journal of Immunology	Aug 2004	84
28	Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons Anna Wald, David M. Koelle, Kenneth H. Fife et al. · Vaccine	22 Sep 2011	81
29	Vaccination with heat shock protein–peptide complexes: from basic science to clinical applications Axel Hoos, Daniel L. Levey · Expert Review of Vaccines	Jun 2003	80
30	Resection of the sciatic, peroneal, or tibial nerves: Assessment of functional status Ari D. Brooks, Jason S. Gold, Dennis Graham et al. · Annals of Surgical Oncology	2002	74
31	Herpesviruses assimilate kinesin to produce motorized viral particles Caitlin E. Pegg, Sofia Zaichick, Ewa K. Bomba-Warczak et al. · Nature Open access	17 Nov 2021	67
32	High-Affinity Interactions between Peptides and Heat Shock Protein 70 Augment CD8+ T Lymphocyte Immune Responses Jessica Baker Flechtner, Kenya Prince Cohane, Sunil Mehta et al. · The Journal of Immunology	Jul 2006	65
33	Characterization of guinea‐pig group 1 CD1 proteins Kenji Hiromatsu, Christopher C. Dascher, Masahiko Sugita et al. · Immunology Open access	29 May 2002	63
34	Current vaccine adjuvants: an overview of a diverse class Charlotte Read Kensil · Frontiers in bioscience Open access	2004	60
35	Heat Shock Proteins and Their Use as Anticancer Vaccines Giorgio Parmiani, Alessandro Testori, Michele Maio et al. · Clinical Cancer Research	15 Dec 2004	59
36	Cutting Edge: Epigenetic Regulation of Foxp3 Defines a Stable Population of CD4+ Regulatory T Cells in Tumors from Mice and Humans Jeremy D. Waight, Shinji Takai, Bo Marelli et al. · The Journal of Immunology Open access	30 Dec 2014	59
37	An Endoplasmic Reticulum Protein Implicated in Chaperoning Peptides to Major Histocompatibility of Class I Is an Aminopeptidase Antoine Ménoret, Zihai Li, Maria L. Niswonger et al. · Journal of Biological Chemistry Open access	Sep 2001	57
38	Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings Eric Jonasch, Christopher G. Wood, Pheroze Tamboli et al. · British Journal of Cancer Open access	25 Mar 2008	56
39	Esterase activity of carbonic anhydrases serves as surrogate for selecting antibodies blocking hydratase activity Narasimha Rao Uda, Volker Seibert, Frank Stenner et al. · Journal of Enzyme Inhibition and Medicinal Chemistry Open access	16 Mar 2015	54
40	TCR Fingerprinting and Off-Target Peptide Identification Armen R Karapetyan, Chawaree Chaipan, Katharina Winkelbach et al. · Frontiers in Immunology Open access	22 Oct 2019	51
41	Epidermal powder immunization of mice and monkeys with an influenza vaccine Dexiang Chen, Ryan L. Endres, Yuh‐Fun Maa et al. · Vaccine	5 Apr 2003	50
42	Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy Dhan Chand et al. · Cancer Discovery Open access	31 Jul 2024	49
43	LBA O-9 Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer Andrea J. Bullock et al. · Annals of Oncology Open access	Jun 2022	48
44	Bioinformatic methods for cancer neoantigen prediction Sebastian Boegel, John C. Castle, Julia Kodysh et al. · Progress in molecular biology and translational science Book chapter	2019	46
45	Direct Measurement of Antigen Binding Properties of CD1 Proteins Using Fluorescent Lipid Probes Jin S. Im, Karl O. A. Yu, Petr A. Illarionov et al. · Journal of Biological Chemistry Open access	24 Dec 2003	46
46	A heat shock protein based polyvalent vaccine targeting HSV-2: CD4+ and CD8+ cellular immunity and protective efficacy Annie X.Y. Mo, Cristina Musselli, Hong Chen et al. · Vaccine	23 Jul 2011	44
47	A strong CD8+ T cell response is elicited using the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei together with the adjuvant QS-21: quantitative and phenotypic comparison with the vaccine model of irradiated sporozoites Valentin Meraldi, Jackeline F. Romero, Charlotte Read Kensil et al. · Vaccine	16 Dec 2004	42
48	A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome Terese Hammond et al. · Nature Communications Open access	6 Feb 2024	40
49	Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood–brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas Kwangsoo Kim et al. · Neuro-Oncology Open access	19 Jul 2024	36
50	The manufacturing considerations of bispecific antibodies Dennis J. Underwood, Jeffrey Bettencourt, Zahra Jawad · Expert Opinion on Biological Therapy	30 Jun 2022	35

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.